Dyne Therapeutics Company Leadership
| DYN Stock | USD 13.91 0.14 1.00% |
About 94 percent of Dyne Therapeutics' insiders are activelly selling. The analysis of the overall insider sentiment regarding Dyne Therapeutics suggests that quite a large number of insiders are panicking. Dyne Therapeutics employs about 173 people. The company is managed by 17 executives with a total tenure of roughly 404 years, averaging almost 23.0 years of service per executive, having 10.18 employees per reported executive.
Insider Sentiment 6
Mostly Selling
Selling | Buying |
Latest Trades
| 2024-12-11 | Richard William Scalzo | Disposed 1455 @ 28.12 | View | ||
| 2024-11-18 | Carlo Incerti | Disposed 16500 @ 28.73 | View | ||
| 2024-11-14 | Jason P Rhodes | Disposed 782 @ 33.1 | View | ||
| 2024-10-16 | Dirk Kersten | Disposed 23671 @ 35.35 | View | ||
| 2024-09-25 | Dirk Kersten | Disposed 2357 @ 35.06 | View | ||
| 2024-09-23 | Dirk Kersten | Disposed 40831 @ 35.32 | View | ||
| 2024-09-20 | Dirk Kersten | Disposed 79411 @ 36.45 | View | ||
| 2024-09-18 | Oxana Beskrovnaya | Disposed 2339 @ 34.55 | View | ||
| 2024-09-04 | John Cox | Acquired 32000 @ 33.04 | View | ||
| 2024-06-24 | Susanna Gatti High | Disposed 10163 @ 35.33 | View | ||
| 2024-06-21 | Susanna Gatti High | Disposed 29787 @ 35.01 | View | ||
| 2024-06-12 | Susanna Gatti High | Disposed 40000 @ 33.36 | View | ||
| 2024-06-11 | Oxana Beskrovnaya | Disposed 2136 @ 31.34 | View | ||
| 2024-06-10 | Susanna Gatti High | Disposed 80000 @ 30.24 | View | ||
| 2024-05-20 | Oxana Beskrovnaya | Disposed 30426 @ 32.96 | View | ||
| 2024-05-16 | Susanna Gatti High | Disposed 2738 @ 28.27 | View |
Monitoring Dyne Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Dyne |
Dyne Therapeutics Management Team Effectiveness
The company has Return on Asset of (0.4035) % which means that on every $100 spent on assets, it lost $0.4035. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6868) %, meaning that it generated no profit with money invested by stockholders. Dyne Therapeutics' management efficiency ratios could be used to measure how well Dyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of February 2025, Return On Tangible Assets is likely to grow to -1.56. In addition to that, Return On Capital Employed is likely to grow to -2.32. As of the 16th of February 2025, Debt To Assets is likely to grow to 0.26, while Total Assets are likely to drop about 141.1 M.As of the 16th of February 2025, Common Stock Shares Outstanding is likely to drop to about 51 M. In addition to that, Net Loss is likely to grow to about (143.7 M)
Dyne Therapeutics Workforce Comparison
Dyne Therapeutics is rated # 5 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,681. Dyne Therapeutics holds roughly 173 in number of employees claiming about 6% of equities under Health Care industry.
Dyne Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Dyne Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.48 | 12 | 25 | 830,500 | 528,944 |
| 2024-09-01 | 0.1529 | 13 | 85 | 565,978 | 2,346,107 |
| 2024-06-01 | 0.375 | 12 | 32 | 351,387 | 418,937 |
| 2024-03-01 | 0.1812 | 27 | 149 | 3,546,545 | 6,150,397 |
| 2023-12-01 | 1.0909 | 12 | 11 | 1,133,619 | 30,827 |
| 2023-09-01 | 0.0909 | 1 | 11 | 35,000 | 33,852 |
| 2023-06-01 | 0.5556 | 10 | 18 | 467,430 | 723,607 |
| 2023-03-01 | 0.0909 | 1 | 11 | 10,000 | 94,078 |
| 2022-12-01 | 1.4545 | 16 | 11 | 2,932,162 | 245,865 |
| 2022-09-01 | 2.1111 | 19 | 9 | 724,869 | 31,310 |
| 2022-06-01 | 1.8333 | 11 | 6 | 215,556 | 6,573 |
| 2022-03-01 | 0.1429 | 1 | 7 | 39,193 | 11,888 |
| 2021-12-01 | 6.0 | 12 | 2 | 682,832 | 7,000 |
| 2021-09-01 | 0.1 | 1 | 10 | 25,000 | 828,050 |
| 2020-09-01 | 1.1667 | 56 | 48 | 73,162,188 | 145,064,158 |
| 2018-03-01 | 0.5 | 6 | 12 | 676,154 | 5,390,235 |
| 2017-12-01 | 0.5 | 1 | 2 | 22,932 | 79,956 |
| 2017-03-01 | 1.2222 | 11 | 9 | 893,276 | 129,377 |
| 2016-03-01 | 1.6667 | 10 | 6 | 674,487 | 30,797 |
| 2015-12-01 | 0.6667 | 2 | 3 | 16,400 | 21,655 |
| 2015-06-01 | 0.2593 | 7 | 27 | 192,699 | 5,000,000 |
| 2015-03-01 | 0.2727 | 6 | 22 | 298,476 | 3,022,260 |
| 2014-12-01 | 0.25 | 3 | 12 | 6,490 | 2,027,503 |
| 2014-06-01 | 0.1111 | 4 | 36 | 14,467 | 6,940,000 |
| 2014-03-01 | 0.2647 | 9 | 34 | 497,054 | 3,071,540 |
| 2013-06-01 | 10.0 | 10 | 1 | 24,185 | 10,161 |
| 2013-03-01 | 8.0 | 8 | 1 | 268,563 | 461,504 |
| 2012-12-01 | 1.0 | 29 | 29 | 3,439,099 | 4,301,587 |
| 2012-06-01 | 20.0 | 20 | 1 | 14,804,194 | 0.00 |
| 2012-03-01 | 3.5 | 7 | 2 | 170,832 | 38,541 |
| 2011-09-01 | 1.5 | 21 | 14 | 3,529,092 | 120,450 |
| 2011-06-01 | 3.5 | 7 | 2 | 19,117 | 0.00 |
| 2011-03-01 | 3.3333 | 10 | 3 | 18,189,886 | 1,610 |
| 2010-06-01 | 4.0 | 4 | 1 | 14,189 | 9,574 |
| 2009-03-01 | 4.6667 | 14 | 3 | 1,297,546 | 13,287 |
| 2007-09-01 | 1.5 | 6 | 4 | 26,816 | 42,000 |
| 2007-06-01 | 1.3 | 39 | 30 | 340,997,811 | 418,956 |
| 2007-03-01 | 1.3333 | 4 | 3 | 6,581 | 14,313 |
| 2006-06-01 | 4.0 | 4 | 1 | 9,927 | 0.00 |
| 2006-03-01 | 10.0 | 10 | 1 | 254,984 | 0.00 |
| 2005-12-01 | 0.3333 | 4 | 12 | 10,202 | 127,913 |
Dyne Therapeutics Notable Stakeholders
A Dyne Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Dyne Therapeutics often face trade-offs trying to please all of them. Dyne Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Dyne Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joshua Brumm | President CEO | Profile | |
| Kate Mitchell | VP Resources | Profile | |
| Romesh Subramanian | CoFounder Advisor | Profile | |
| Richard MBA | Senior Administration | Profile | |
| Ashish MBA | Chief Officer | Profile | |
| Oxana Beskrovnaya | Chief Officer | Profile | |
| Johanna FriedlNaderer | Chief Officer | Profile | |
| Lucia Celona | Chief Officer | Profile | |
| Daniel Wilson | Senior Legal | Profile | |
| MBA MD | Chief Officer | Profile | |
| Susanna MBA | Chief Officer | Profile | |
| MS MD | VP Pharmacovigilance | Profile | |
| Debra Feldman | Chief Officer | Profile | |
| John MBA | Chief Officer | Profile | |
| Gene Kim | VP Fin | Profile | |
| Amy Reilly | Senior Relations | Profile | |
| Jonathan MD | Chief Officer | Profile |
About Dyne Therapeutics Management Performance
The success or failure of an entity such as Dyne Therapeutics often depends on how effective the management is. Dyne Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Dyne management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Dyne management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.64) | (1.56) | |
| Return On Capital Employed | (2.44) | (2.32) | |
| Return On Assets | (1.64) | (1.56) | |
| Return On Equity | (2.97) | (2.82) |
Dyne Therapeutics Workforce Analysis
Traditionally, organizations such as Dyne Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Dyne Therapeutics within its industry.Dyne Therapeutics Manpower Efficiency
Return on Dyne Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 13.9M | |
| Working Capital Per Employee | 452.5K | |
| Working Capital Per Executive | 4.6M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.